Atazanavir

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Virustatic. Inhibitor of HIV protease.

IndicationThis section has been translated automatically.

Antiretroviral combination therapy for the treatment of HIV-1 infection in experienced patients, in particular those pre-treated with protease inhibitors.

Notice!

Consideration of the viral resistance pattern and pretreatment of the patient, especially with other protease inhibitors!

Pregnancy/nursing periodThis section has been translated automatically.

Contraindicated during pregnancy and lactation (insufficient data available).

Dosage and method of useThis section has been translated automatically.

Adults > 18 years: once/day 400 mg p.o.In combination with ritonavir : once/day 300 mg p.o.

Undesirable effectsThis section has been translated automatically.

Diarrhea, headache, reversible hyperbilirubinemia (icterus)

ContraindicationThis section has been translated automatically.

Hypersensitivity to the substance, comedication with benzodiazepines (midazolam, triazolam), ergotamine derivatives, cisapride, neuroleptics.

PreparationsThis section has been translated automatically.

Reyataz

Authors

Last updated on: 29.10.2020

Author: Prof. Dr. med. Peter Altmeyer